Literature DB >> 27958298

Sarcoma in 2016: Evolving biological understanding and treatment of sarcomas.

Jean-Yves Blay1, Isabelle Ray-Coquard1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27958298     DOI： 10.1038/nrclinonc.2016.200

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Monogenic and polygenic determinants of sarcoma risk: an international genetic study.

Authors:  Mandy L Ballinger; David L Goode; Isabelle Ray-Coquard; Paul A James; Gillian Mitchell; Eveline Niedermayr; Ajay Puri; Joshua D Schiffman; Gillian S Dite; Arcadi Cipponi; Robert G Maki; Andrew S Brohl; Ola Myklebost; Eva W Stratford; Susanne Lorenz; Sung-Min Ahn; Jin-Hee Ahn; Jeong Eun Kim; Sue Shanley; Victoria Beshay; Robert Lor Randall; Ian Judson; Beatrice Seddon; Ian G Campbell; Mary-Anne Young; Rajiv Sarin; Jean-Yves Blay; Seán I O'Donoghue; David M Thomas
Journal:  Lancet Oncol       Date:  2016-08-04       Impact factor: 41.316

2.  Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: 
Journal:  Ann Oncol       Date:  2014-09       Impact factor: 32.976

3.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Authors:  Ian Judson; Jaap Verweij; Hans Gelderblom; Jörg T Hartmann; Patrick Schöffski; Jean-Yves Blay; J Martijn Kerst; Josef Sufliarsky; Jeremy Whelan; Peter Hohenberger; Anders Krarup-Hansen; Thierry Alcindor; Sandrine Marreaud; Saskia Litière; Catherine Hermans; Cyril Fisher; Pancras C W Hogendoorn; A Paolo dei Tos; Winette T A van der Graaf
Journal:  Lancet Oncol       Date:  2014-03-05       Impact factor: 41.316

4.  Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.

Authors:  Sosipatros A Boikos; Alberto S Pappo; J Keith Killian; Michael P LaQuaglia; Chris B Weldon; Suzanne George; Jonathan C Trent; Margaret von Mehren; Jennifer A Wright; Josh D Schiffman; Margarita Raygada; Karel Pacak; Paul S Meltzer; Markku M Miettinen; Constantine Stratakis; Katherine A Janeway; Lee J Helman
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

5.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Authors:  Patrick Schöffski; Sant Chawla; Robert G Maki; Antoine Italiano; Hans Gelderblom; Edwin Choy; Giovanni Grignani; Veridiana Camargo; Sebastian Bauer; Sun Young Rha; Jean-Yves Blay; Peter Hohenberger; David D'Adamo; Matthew Guo; Bartosz Chmielowski; Axel Le Cesne; George D Demetri; Shreyaskumar R Patel
Journal:  Lancet       Date:  2016-02-10       Impact factor: 79.321

6.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Authors:  George D Demetri; Margaret von Mehren; Robin L Jones; Martee L Hensley; Scott M Schuetze; Arthur Staddon; Mohammed Milhem; Anthony Elias; Kristen Ganjoo; Hussein Tawbi; Brian A Van Tine; Alexander Spira; Andrew Dean; Nushmia Z Khokhar; Youn Choi Park; Roland E Knoblauch; Trilok V Parekh; Robert G Maki; Shreyaskumar R Patel
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

7.  PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Authors:  Christopher W Ryan; Ofer Merimsky; Mark Agulnik; Jean-Yves Blay; Scott M Schuetze; Brian A Van Tine; Robin L Jones; Anthony D Elias; Edwin Choy; Thierry Alcindor; Vicki L Keedy; Damon R Reed; Robert N Taub; Antoine Italiano; Xavier Garcia Del Muro; Ian R Judson; Jill Y Buck; Francois Lebel; Jonathan J Lewis; Robert G Maki; Patrick Schöffski
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

8.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Authors:  William D Tap; Robin L Jones; Brian A Van Tine; Bartosz Chmielowski; Anthony D Elias; Douglas Adkins; Mark Agulnik; Matthew M Cooney; Michael B Livingston; Gregory Pennock; Meera R Hameed; Gaurav D Shah; Amy Qin; Ashwin Shahir; Damien M Cronier; Robert Ilaria; Ilaria Conti; Jan Cosaert; Gary K Schwartz
Journal:  Lancet       Date:  2016-06-09       Impact factor: 79.321

9.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

Authors:  Sharon E Plon; Diana M Eccles; Douglas Easton; William D Foulkes; Maurizio Genuardi; Marc S Greenblatt; Frans B L Hogervorst; Nicoline Hoogerbrugge; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878
  9 in total
  8 in total

1.  Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma.

Authors:  Alessandro De Vita; Laura Mercatali; Giacomo Miserocchi; Chiara Liverani; Chiara Spadazzi; Federica Recine; Alberto Bongiovanni; Federica Pieri; Davide Cavaliere; Valentina Fausti; Dino Amadori; Toni Ibrahim
Journal:  J Vis Exp       Date:  2018-04-11       Impact factor: 1.355

2.  Patient and Oncologist Preferences for the Treatment of Adults with Advanced Soft Tissue Sarcoma: A Discrete Choice Experiment.

Authors:  Jasmina Ivanova; Lisa M Hess; Viviana Garcia-Horton; Sophia Graham; Xinyue Liu; Yajun Zhu; Steven Nicol
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

Review 3.  Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development.

Authors:  Daniel Y Lee; Arthur P Staddon; Jacob E Shabason; Ronnie Sebro
Journal:  Cancer Med       Date:  2019-01-10       Impact factor: 4.452

4.  Systematic profiling of diagnostic and prognostic value of autophagy-related genes for sarcoma patients.

Authors:  Yuanhe Wang; Jianyi Li; Cheng Shao; Xiaojie Tang; Yukun Du; Tongshuai Xu; Zheng Zhao; Huiqiang Hu; Yingyi Sheng; Chuan Hu; Yongming Xi
Journal:  BMC Cancer       Date:  2021-01-12       Impact factor: 4.430

5.  Comprehensive analysis of metabolism-related lncRNAs related to the progression and prognosis in osteosarcoma from TCGA.

Authors:  Xingyin Chen; Zhengyun Ye; Pan Lou; Wei Liu; Ying Liu
Journal:  J Orthop Surg Res       Date:  2021-08-23       Impact factor: 2.359

6.  A novel immune-related gene signature predicting survival in sarcoma patients.

Authors:  Haoyu Ren; Alexandr V Bazhin; Elise Pretzsch; Sven Jacob; Haochen Yu; Jiang Zhu; Markus Albertsmeier; Lars H Lindner; Thomas Knösel; Jens Werner; Martin K Angele; Florian Bösch
Journal:  Mol Ther Oncolytics       Date:  2021-12-09       Impact factor: 7.200

Review 7.  On the Relevance of Soft Tissue Sarcomas Metabolic Landscape Mapping.

Authors:  Miguel Esperança-Martins; Iola F Duarte; Mara Rodrigues; Joaquim Soares do Brito; Dolores López-Presa; Luís Costa; Isabel Fernandes; Sérgio Dias
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

Review 8.  Metabolic landscapes in sarcomas.

Authors:  Richard Miallot; Franck Galland; Virginie Millet; Jean-Yves Blay; Philippe Naquet
Journal:  J Hematol Oncol       Date:  2021-07-22       Impact factor: 17.388
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.